Treatment for Secondary HLH Post-Partum Due to EBV

Initial Assessment and Treatment Strategy

The American Society of Hematology recommends a graded intensity approach for treating EBV-HLH, with mortality rates ranging from 20-88% if not properly treated 1, 2
For patients with less severe disease, the European Society for Medical Oncology suggests starting with a short course of corticosteroids (prednisolone 1-2 mg/kg or dexamethasone 5-10 mg/m²) with or without IVIG (1.6 g/kg over 2-3 days) 1, 3
For rapidly deteriorating patients, the American Society of Hematology recommends initiating etoposide treatment without delay according to HLH-94 protocol 1, 2
Regular monitoring of ferritin, soluble CD25 (IL-2 receptor), complete blood counts, and EBV DNA levels is essential to assess treatment response, as recommended by the American College of Physicians 1, 3

The American Society of Hematology recommends adding rituximab (375 mg/m² once weekly for 2-4 doses) to HLH-directed therapy to clear the B-cell reservoir of EBV 1, 2, 4
The European Society for Medical Oncology notes that EBV-HLH involves infection of T cells and/or NK cells, so rituximab cannot replace anti-T-cell therapy with corticosteroids with/without etoposide 1, 2
The American College of Physicians recommends monitoring EBV DNA levels closely, as levels >10³ copies per milliliter are relevant for the development of EBV-HLH 1
The Infectious Diseases Society of America states that antiviral drugs are not effective against EBV and are not recommended for EBV prophylaxis or therapy 4, 5

For all patients with confirmed EBV-HLH, the American Society of Hematology recommends starting corticosteroids (dexamethasone 5-10 mg/m²) and adding rituximab 375 mg/m² weekly (1-4 doses) until EBV DNA-emia negativity 1, 2, 4
For patients with mild-moderate disease, the European Society for Medical Oncology suggests continuing corticosteroids and rituximab, and considering adding IVIG 1.6 g/kg over 2-3 days 1, 3, 5
For patients with severe disease or rapid deterioration, the American Society of Hematology recommends immediately initiating etoposide according to HLH-94 protocol, continuing rituximab and corticosteroids, and using etoposide sparingly to allow bone marrow recovery for immune reconstitution 1, 2

The American College of Physicians recommends assessing treatment response through regular monitoring of ferritin levels, soluble CD25 (IL-2 receptor) levels, complete blood counts, EBV DNA levels, and liver function tests 1, 2, 6
The American Society of Hematology notes that response to rituximab therapy can be identified by a decrease in EBV DNA-emia of at least 1 log10 in the first week of treatment 4, 5

The American Academy of Pediatrics notes that younger age is a favorable factor predicting outcome to rituximab-based therapy 4, 5
The Infectious Diseases Society of America states that secondary infections are a major cause of mortality in HLH patients and require vigilant monitoring 1, 6
The American Society of Hematology recommends contact with an HLH reference center for complex cases 1, 2

The European Society for Medical Oncology recommends that the treatment goal is resolution of all signs and symptoms of HLH, including a negative viral load 4, 5
The American Society of Hematology notes that positive prognostic factors for outcome to rituximab therapy include age below 30 years, underlying non-malignant disease, and decrease of EBV DNA-emia after initial therapy 4, 5